What is the primary purpose of the $5 billion share repurchase program?

The $5 billion share repurchase program is a capital allocation strategy by Johnson & Johnson's Board of Directors to return value to shareholders. The shares repurchased will be available for general corporate purposes, which could include offsetting dilution from stock-based compensation, funding future acquisitions, or simply reducing the number of outstanding shares to potentially boost EPS.

How will Johnson & Johnson fund these share repurchases?

Johnson & Johnson stated that it does not expect to incur debt to fund this share repurchase program. This suggests the company anticipates using its existing cash reserves or internally generated cash flows to finance the buybacks, indicating financial strength and flexibility.

When will the share repurchases begin and end?

The share repurchase program has no time limit and may be suspended or discontinued at any time at the discretion of management. Repurchases may be made from time to time on the open market or through privately negotiated transactions.

Does the reaffirmation of guidance mean JNJ expects to meet or exceed its previous forecasts?

Reaffirming guidance means Johnson & Johnson continues to expect its full-year performance to align with the previously announced mid-point targets for adjusted operational sales growth of 7% and adjusted operational EPS of $10.70 (9.2% growth). It indicates confidence in current business trends and the ability to achieve these financial objectives.

JNJ 8-K SEC Disclosure — Sep 14, 2022

Summary

Johnson & Johnson (JNJ) announced a significant capital allocation decision through its Board of Directors authorizing a new share repurchase program of up to $5 billion. This move signals management's confidence in the company's financial health and its commitment to returning value to shareholders. The program has no fixed expiration and allows for flexibility in execution, with repurchases potentially occurring on the open market or through private negotiations. Importantly, the company stated it does not anticipate incurring debt to fund these repurchases, indicating sufficient internal cash flow generation. In addition to the share buyback authorization, Johnson & Johnson reaffirmed its full-year financial guidance. The company maintains its outlook for adjusted operational sales growth of 7% (projected at $97.8 billion) and adjusted operational earnings per share (EPS) growth of 9.2% (projected at $10.70). This reaffirmation, coupled with the significant share repurchase authorization, suggests a stable and positive outlook for JNJ's performance through the remainder of 2022.

Key Highlights

1Johnson & Johnson's Board of Directors authorized a $5 billion share repurchase program.
2The repurchase program is flexible, with no set time limit and discretion over execution methods (open market or private transactions).
3The company does not expect to use debt to finance the share repurchases.
4Shares acquired will be available for general corporate purposes.
5JNJ reaffirmed its full-year guidance for adjusted operational sales growth of 7% ($97.8 billion).
6The company also reaffirmed its full-year guidance for adjusted operational EPS growth of 9.2% ($10.70).

JOHNSON & JOHNSON 8-K Report, Corporate Update (Sep 14, 2022)

Summary

Key Highlights

Frequently Asked Questions